Inpatient MOUD Linked to Reduced One-Year Mortality in OUD Patients with Invasive Bacterial Infections

Overview

This retrospective study found that administration of medications for opioid use disorder (MOUD) during hospitalization for invasive bacterial infections in patients with opioid use disorder (OUD) is associated with decreased one-year all-cause mortality. The analysis included adults aged 18–65 with documented opioid use and invasive infections, highlighting the potential mortality benefit of inpatient MOUD treatment.

Background

Invasive bacterial infections such as endocarditis are common and serious complications among people with opioid use disorder. Standard treatment often requires prolonged intravenous antibiotics, necessitating extended hospital stays. Patients with OUD frequently face barriers to outpatient care and are often disengaged from traditional healthcare systems. Hospitalization presents a critical opportunity to initiate MOUD, which has been shown to reduce mortality in outpatient settings, but its impact when started inpatient has been unclear.

Data Highlights

The study reviewed hospital admissions from February 2020 to July 2023 at Columbia University Irving Medical Center, including patients with recent opioid use hospitalized for endocarditis and other invasive bacterial infections. Inclusion criteria were age 18–65, positive blood cultures for invasive pathogens, and documented opioid use within the prior year. MOUD exposure was defined as receiving buprenorphine, methadone, or naltrexone for at least 50% of hospital days. The primary outcome was one-year all-cause mortality, including in-hospital deaths.

Key Findings

• Inpatient administration of MOUD was associated with a significant reduction in one-year all-cause mortality among patients with OUD hospitalized for invasive bacterial infections.
• Patients receiving MOUD during hospitalization had improved antibiotic adherence and reduced rates of patient-directed discharge and readmission in prior studies.
• Despite recommendations, linkage to outpatient MOUD after hospitalization remains low, underscoring the importance of inpatient initiation.
• The study included patients using opioids via injection and noninjection routes, broadening applicability.
• Housing instability and other social determinants were considered in patient characterization, reflecting real-world complexity.

Clinical Implications

Clinicians should consider initiating MOUD during hospitalization for invasive bacterial infections in patients with OUD to reduce mortality risk. Hospital stays offer a vital window to engage this population in addiction treatment and improve long-term outcomes. Integrating addiction services with infectious disease care may enhance treatment adherence and survival.

Conclusion

Inpatient MOUD administration is associated with decreased one-year mortality in patients with opioid use disorder hospitalized for invasive bacterial infections, supporting guidelines recommending initiation of MOUD during hospitalization. This approach represents a critical intervention to improve survival in this high-risk population.

References

1. Infectious Diseases Society of America Guidelines -- Antibiotic Treatment of Bacteremia and Endocarditis
2. Prior Studies on MOUD and Clinical Outcomes (References 17–20)
3. Centers for Disease Control and Prevention -- Definition of Housing Instability